**MEMORANDUM**

**TO:** Board of Directors and CEO, Northgate Metrics
**FROM:** Counsel
**DATE:** [Current Date]
**RE:** Urgent Legal Advice Regarding Series B Deck Misstatements and Financing Risks

This advice addresses the critical legal and fiduciary risks surrounding the proposed Series B financing. **The CEO’s proposal to “sign on schedule” and fix metrics later exposes the Company, the Directors, and the Officers to severe liability for securities fraud.** We must treat this as a crisis of disclosure integrity, not merely a pricing negotiation.

### 1. Misstatements vs. Protected Projections
Under Rule 10(b)-5 and applicable state law, the antifraud prohibitions apply to private placements.
*   **ARR Figure ($14.2M):** This is presented as a statement of present fact ("ARR: $14.2M"). It describes the current financial status of the company. Including one-time implementation fees ($2.6M) and terminable, not-yet-live contracts ($1.1M) in "Recurring Revenue" constitutes an untrue statement of material fact regarding revenue recognition standards.
*   **Retention Figure (138%):** By excluding specific lost accounts to manufacture this number, the Company is presenting a selective historical reality as comprehensive data. This is a misstatement of historical fact, not a forecast.
*   **Disclaimer:** The slide disclaimer stating projections "involve risks and uncertainties" is **boilerplate**. Under Rule 3, boilerplate cautions are not "meaningful, specific cautionary language." Furthermore, the protection for forward-looking statements does not extend to misstatements of present or historical fact (Rule 3).
*   **Conclusion:** Neither figure qualifies for forward-looking protection. Both are actionable misrepresentations of fact.

### 2. Materiality Analysis
A fact is material if a reasonable investor would consider it important in the "total mix" of information.
*   **ARR Gap:** The stated ARR ($14.2M) exceeds true recurring revenue ($10.5M) by $3.7 million, or **26%**. In venture financing, SaaS valuation is driven almost exclusively by ARR multiples. A 26% overstatement of the top-line growth metric is objectively material.
*   **Retention Gap:** The discrepancy between 138% (deck) and 111% (actual) masks significant churn risk regarding major accounts. This alters the assessment of unit economics and cohort health.
*   **Non-Renewal Notice:** A customer representing **9% of subscription revenue** has notified non-renewal within four months. This is material information regarding future cash flow. Omitting this while soliciting capital creates a misleading picture of financial stability.
*   **Conclusion:** All three discrepancies are highly material. No reasonable investor would consider these immaterial; indeed, they likely determine the investment thesis entirely.

### 3. Scienter and Liability Exposure
Liability requires scienter (intent or recklessness). The CFO’s email ("Keep the number. We can true it up after") is a smoking gun for **specific intent to deceive**.
*   **CFO:** Direct liability for making the misrepresentation. Indemnification will not cover fraud (Rule 7).
*   **CEO:** By receiving the deck and proposing to sign despite the knowledge of its flaws, the CEO risks aiding and abetting or primary liability. Personal insurance exposure is triggered.
*   **Directors:** Approving a financing "known to rest on misleading materials" implicates the duty of loyalty, not merely care (Rule 6). Directors could be held personally liable for breach of fiduciary duty.
*   **Company:** The entity itself faces rescission claims and potential SEC action for private offering fraud.

### 4. The Anchor Investor ($8M Wired)
*   **Status:** The investor has signed and wired funds. They are "irrevocably committed."
*   **Reliance:** Under Rule 4, correction *after* irrevocable commitment does not cut off reliance for that investor.
*   **Remedies:** Because they relied on the fraud, they may seek rescission (return of $8M + interest) or damages.
*   **Action:** We cannot simply disclose and hope it cures them. We must proactively offer a resolution to limit litigation risk. This likely requires offering the anchor investor the option to withdraw or renegotiate terms based on the true metrics, acknowledging their reliance was induced by misstatement.

### 5. The Unsigned $32 Million
*   **Status:** Committed but unsigned. Not yet irrevocably committed.
*   **Rule 4 Application:** Correction of a misstatement before an investor becomes irrevocably committed *can* cut off reliance.
*   **Required Action:** We must revise the deck and provide full disclosure to all prospective investors **before** signing the Subscription Agreements. The corrected materials must explicitly state:
    1.  Corrected ARR ($10.5M).
    2.  Corrected NRR (111%).
    3.  Disclosure of the 9% customer non-renewal notice.
*   **Consequence:** If we sign without this correction, the remaining $32M investors will have clear claims for rescission and damages, and the deal will likely collapse during post-closing diligence.

### 6. Founder Secondary Sale
*   **Rule 5:** Selling securities while in possession of material nonpublic information (MNPI) to a buyer without that information violates antifraud rules.
*   **Fact:** The founder knows about the 9% customer non-renewal; investors do not.
*   **Conclusion:** The secondary sale **cannot proceed** under current conditions. To sell now would be selling based on MNPI (the churn risk that will devalue the company).
*   **Conditions:** If the Company discloses the non-renewal notice to *all* investors as part of the general correction, the information is no longer "nonpublic" regarding the offering participants, and the sale could theoretically proceed. However, this disclosure may cause investors to rescind or lower the valuation for the secondary shares. Given the timing (12 days), it is safer to pause the secondary until the primary financing is restructured on honest terms.

### 7. Board Position and Exculpation
*   **Duty of Candor:** If the Board follows the CEO’s proposal, they breach their duty of candor to shareholders by validating misleading disclosures (Rule 6).
*   **Insurance/Indemnification:** Under Rule 7, D&O insurance and indemnification do not cover liability finally adjudicated to arise from fraud. By knowingly approving the current deck, Board members expose their personal assets to unlimited liability.
*   **Action:** The Board must formally reject the CEO’s proposal and mandate immediate correction of the records.

### 8. Repricing Conversation & Strategy
*   **Valuation Impact:** The $220M valuation was priced off $14.2M ARR (approx. 15.5x). On true recurring revenue ($10.5M), the same price implies a ~20x multiple, which may be unsustainable given the churn.
*   **Strategy:** We anticipate investors will demand a price adjustment or increased deal size to maintain their valuation per share.
*   **Recommendation:** Delay and Reprice. Attempting to hide this will likely result in the deal failing later when the numbers are discovered during post-investment due diligence or Series C. A clean break now, even at a slightly lower valuation, preserves the company’s integrity and prevents future litigation that could freeze assets.

### 9. Concrete 48-Hour Plan for Counsel

**Hour 0–12: Immediate Preservation & Board Meeting**
1.  **Secure Evidence:** Preserve all communications regarding deck preparation, specifically the CFO's email. Do not destroy any records.
2.  **Board Call:** Convene the Board immediately (within 6 hours). Present this memorandum. Obtain a formal Board Resolution rejecting the current deck and authorizing counsel to negotiate corrections with investors. Document that Directors are acting to mitigate fraud risk, preserving their good-faith defense.

**Hour 12–24: Drafting Corrective Disclosure**
1.  **New Deck:** Draft "Series B Amendment" materials showing True ARR ($10.5M), True NRR (111%), and footnote the non-renewal risk.
2.  **Disclosure Letter:** Prepare a cover letter admitting the overstatement of metrics in prior diligence, explaining the accounting discrepancy (one-time fees vs. recurring), and disclosing the non-renewal notice.

**Hour 24–36: Investor Communication Strategy**
1.  **Anchor Investor ($8M):** CEO and Board Chair must call the anchor investor lead immediately. Present the facts transparently. Offer a "Cure Agreement": Anchor may remain invested at current valuation, but Company warrants no future claims regarding prior metrics; *or* offer rescission if they prefer. Do not rely on the original contract in good conscience.
2.  **Remaining Investors ($32M):** Halt all signing activities immediately. Send Corrective Disclosure materials to all participants. State that signing will proceed only after acknowledgment of the revised metrics.
3.  **Founder Secondary:** Notify Founder that the secondary sale is suspended pending investor acceptance of the full disclosure package.

**Hour 36–48: Execution or Restructure**
1.  **Board Resolution 2:** Ratify the decision to pause signing and restructure based on honest metrics. Explicitly record that this was done to prevent fraud liability.
2.  **Term Sheet Amendment:** Negotiate revised valuation or investment amounts with lead investors based on the $10.5M ARR figure.
3.  **Final Sign-off:** No documents are signed until the corrected deck and disclosure letter are delivered and acknowledged by all parties.

**Bottom Line:** We cannot sign the current papers. The CFO’s email proves scienter. Proceeding knowingly converts a commercial dispute into personal liability fraud for the Board and Officers. Fixing the numbers now is painful but necessary to save the company from existential legal risk.